AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Elevance Health Plunges 8.29% on Earnings Miss
Generated by AI AgentAinvest Pre-Market Radar
Thursday, Jul 17, 2025 6:13 am ET1min read
Aime SummaryOn July 17, 2025, Elevance Health's stock price dropped by 8.29% in pre-market trading.
Elevance Health reported its second-quarter 2025 financial results, revealing an operating revenue of $18.1 billion, an operating gain of $0.9 billion, and an adjusted operating gain of $0.9 billion. The company's operating margin stood at 5.2%.
Despite these figures, Elevance Health's earnings per share (EPS) for the quarter missed analyst estimates by $0.23, coming in at $8.84 instead of the expected $9.07. The company's revenue for the quarter was $49.4 billion.
Elevance Health has projected its full-year 2025 EPS to be $30.00, which is lower than the analyst consensus of $34.48. This projection, along with the earnings miss, has contributed to the stock's decline.
Elevance Health's financial results come at a time when other major health insurers, such as
and Corp, have also faced challenges in managing costs and providing guidance for the year. This sector-wide uncertainty has likely added to the pressure on Elevance Health's stock price.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
SEALSQ Surged 8.29% Driven by 2026–2030 Roadmap for Silicon-Based Quantum Computing Systems
Dec.19 2025
Serve Robotics (SERV) Surges 5.97% on Bullish Oppenheimer Note
Dec.19 2025
AXT Inc. shares surge 13.35% on renewed earnings upside speculation amid supply chain adjustments
Dec.19 2025
PROK surged 5.11% on Dec. 19 2025 after HC Wainwright upgraded to Buy rating
Dec.19 2025
Tesla shares surge 3.45% as SpaceX orders 1,000-2,000 Cybertrucks for Starbase facility.
Dec.19 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet